Our theme of Gene Editing stocks remains down by about 11% year-to-date, considerably underperforming the S&P 500 which is up by a solid 23% over the same period. The theme would have actually declined by about 46% year-to-date if we exclude a single stock, Intellia Therapeutics, which is up by...
Bluebird, Editas: Gene Editing Stocks Had A Tough Year. Will 2022 Be Better?
Forbes - 23 Dec 2021 15:30
Our theme of Gene Editing stocks remains down by about 11% year-to-date, considerably underperforming the S&P 500 which is up by a solid 23% over the same period. The theme would have actually declined by about 46% year-to-date if we exclude a single stock, Intellia Therapeutics, which is up by...
Share this Article
Recommended